echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Sanofi's Beijing production base expanded

    Sanofi's Beijing production base expanded

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Sanofi, the world's leading biopharmaceutical company, held a signing ceremony for the insulin expansion project of its production base in Beijing on the 1st and a commemorative event for the 25th anniversary of its establishment in Beijing.
    This move not only shows the French company's firm confidence in the Chinese market, but also fulfills its promise to provide health services to Chinese residents.

     Yin Yong, Member of the Standing Committee of the Beijing Municipal Committee and Deputy Mayor, and French Ambassador to China Mr.
    Luo Liang attended and witnessed the signing ceremony.

     Yin Yong said that Sanofi has invested and built a factory in Beijing for 25 years and has witnessed the process of China's reform and opening up, and has grown together with China.
    In the future, it is hoped that leading companies in the global medical field, including Sanofi, can seize the opportunity of China's reform and opening up to introduce more advanced medical and health products and services into China.

     The French Ambassador to China, Mr.
    Luo Liang, is pleased with the long-term cooperative partnership between China and France in the field of medicine and health.
    He said that Sanofi's history in China is the best example of the long-term partnership between the two countries.

     Dr.
    He Enting, President of Sanofi Greater China, said that the expansion of insulin production is one of Sanofi's measures to improve its overall layout in China.
    It not only shows Sanofi's firm confidence in the Chinese market, but also fulfills its promise to protect the health of the Chinese people.

     With the continuous improvement of Chinese people's living standards and changes in dietary structure, the number of diabetic patients has risen by nearly 120 million, ranking first in the world.

     Zhang Ping, head of Sanofi's China Industrial Affairs Department, said that as one of the first multinational pharmaceutical companies to enter the Chinese market, Sanofi's three production bases in China have always focused on meeting the health service needs of Chinese patients.
    .

     In December 1995, Sanofi's Beijing production base was officially settled in Beijing Economic and Technological Development Zone.
    Following the global unified high-standard quality management system and precise process management, through continuous investment, expansion and upgrading,
    the base already has the world's advanced insulin production lines such as insulin glargine injection filling lines.
    At the same time, the production base drives "green development" with "green production", and was named a "green factory" by the Ministry of Industry and Information Technology of China in 2020.
    (China News Network)

    Sanofi, the world's leading biopharmaceutical company, held a signing ceremony for the insulin expansion project of its production base in Beijing on the 1st and a commemorative event for the 25th anniversary of its establishment in Beijing.
    This move not only shows the French company's firm confidence in the Chinese market, but also fulfills its promise to provide health services to Chinese residents.

     Yin Yong, Member of the Standing Committee of the Beijing Municipal Committee and Deputy Mayor, and French Ambassador to China Mr.
    Luo Liang attended and witnessed the signing ceremony.

     Yin Yong said that Sanofi has invested and built a factory in Beijing for 25 years and has witnessed the process of China's reform and opening up, and has grown together with China.
    In the future, it is hoped that leading companies in the global medical field, including Sanofi, can seize the opportunity of China's reform and opening up to introduce more advanced medical and health products and services into China.

     The French Ambassador to China, Mr.
    Luo Liang, is pleased with the long-term cooperative partnership between China and France in the field of medicine and health.
    He said that Sanofi's history in China is the best example of the long-term partnership between the two countries.

     Dr.
    He Enting, President of Sanofi Greater China, said that the expansion of insulin production is one of Sanofi's measures to improve its overall layout in China.
    It not only shows Sanofi's firm confidence in the Chinese market, but also fulfills its promise to protect the health of the Chinese people.

     With the continuous improvement of Chinese people's living standards and changes in dietary structure, the number of diabetic patients has risen by nearly 120 million, ranking first in the world.

     Zhang Ping, head of Sanofi's China Industrial Affairs Department, said that as one of the first multinational pharmaceutical companies to enter the Chinese market, Sanofi's three production bases in China have always focused on meeting the health service needs of Chinese patients.
    .

     In December 1995, Sanofi's Beijing production base was officially settled in Beijing Economic and Technological Development Zone.
    Following the global unified high-standard quality management system and precise process management, through continuous investment, expansion and upgrading,
    the base already has the world's advanced insulin production lines such as insulin glargine injection filling lines.
    At the same time, the production base drives "green development" with "green production", and was named a "green factory" by the Ministry of Industry and Information Technology of China in 2020.
    (China News Network)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.